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Abstract 
Borosilicate bioactive glasses (BBGs) have shown the capacity to promote a higher 
formation of new bone when compared to silicate bioactive glasses. Herein, we assessed 
the capacity of BBGs to induce the osteogenic differentiation of bone marrow 
mesenchymal stem cells (BM-MSCs), as a function of their substituted divalent cations 
(Mg
2+
, Ca
2+
, Sr
2+
). To this purpose, we synthesized BBG particles by melt quenching. 
The cell viability, proliferation and morphology, (i.e. PrestoBlue
®
, PicoGreen
®
, and 
DAPI and Phalloidin stainings, respectively) as well as protein expression (i.e. alkaline 
phosphatase, ALP, osteopontin, OP, and osteocalcin, OC) of BM-MSCs in contact with 
the BBGs were evaluated for 21 days. We observed an enhanced expression of the 
bone-specific proteins (ALP, OP and OC) and high mineralization of BM-MSCs under 
BBG-Mg and BBG–Sr conditioned osteogenic media for concentrations of 20 and 50 
mg/ml with low cytotoxic effects. Moreover, BBG-Sr, at a concentration of 50 mg/ml, 
was able to increase the mineralization and expression of the same bone-specific 
proteins even under basal media conditions. These results indicated that the proposed 
BBGs improved the osteogenic differentiation of BM-MSCs. Therefore, showing their 
potential as relevant biomaterials for bone tissue regeneration, not only by bonding to 
bone tissue, but also by stimulating new bone formation. 
 
Key words: Borosilicate glasses, strontium, mineralization, osteogenic induction, BM-
MSCs 
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1. Introduction 
The properties of bioactive glasses (BGs) support their key relevance in clinical 
applications associated to bone tissue repair and regeneration. (1, 2) They are part of a 
tissue engineering-based strategy that can overcome the drawbacks of the traditionally 
used autologous bone grafts (e.g. lack of adequate amount and quality of bone, donor 
site morbidity). BGs are considered relevant for bone tissue repair since they: (i) 
promote osteointegration (forming a bone-like hydroxyapatite (HA) layer on their 
surface); (ii) are biocompatible; and (iii) their degradation shows positive biological 
effects after implantation. (2-5) There are, however, drawbacks associated with 
conventional BGs including in vitro cytotoxicity related to the release of Na
+
 ions, and 
interest in modified compositions has increased in recent years. (6) 
Recently, borosilicate bioactive glasses (BBGs) have attracted interest in bone tissue 
engineering. (1, 7, 8) BBGs have shown capability to improve the new bone formation 
when compared to silicate-based BGs. (9, 10) They present controllable degradation 
rates and have a high compositional flexibility that potentially allows BBGs to be 
tailored with enhanced osteogenic and angiogenic properties, as well as with 
antibacterial capacity. (11, 12) On one hand, as shown by Huang et al., a glass network 
composed of borosilicate’s have more controllable conversion rates to HA. (13) This 
has also been demonstrated to occur in vivo. (14) As a matter of fact, the addition of 
borate to the glass network can also be beneficial for bone healing, as well as formation, 
and maintenance of new bone, while supporting cell osteogenic differentiation. (15) 
Frequently, it has been associated with the increase in bone resistance to fracture. (16, 
17) On the other hand, by exploiting the compositional flexibility of BBGs, inorganic 
divalent cations, such as Mg
2+
, Ca
2+
 and Sr
2+
 can be incorporated and play a key role in 
bone metabolism. For instance, Mg
2+
 increases bone formation rate, as well as 
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stimulates bone cell adhesion increasing their stability. (18, 19) The Ca
2+
 is known to be 
essential during the apatite formation process, being also favorable to osteoblast 
proliferation, differentiation and the mineralization of the extracellular matrix (ECM). 
(20) Sr
2+ 
also has bone therapeutic potential. Different studies evidenced its beneficial 
effects on bone cells and bone formation in vivo, (21, 22) being even used for the 
treatment of osteoporosis. (23) 
In general BGs are known to be osteoinductive materials, capable of stimulating the 
function and osteogenic differentiation of bone and stem cells without any additional 
supplementation. Findings from Fu et al. suggested that the borosilicate 13-93B1 
scaffolds supported the proliferation and function of osteogenic Murine Osteocyte-like 
Cell Line MLO-A5,(15) while Gentleman et al. demonstrated that Sr
2+
-substituted BGs 
stimulated osteoblast metabolic activity promoting cell proliferation and ALP activity. 
(24) More significantly, Santocildes et al. demonstrated that Sr-containing BGs 
appeared to be capable of promoting osteoblastic differentiation in a proportion of bone 
marrow mesenchymal stem cells (BM-MSCs) that were in some way pre-committed to 
this lineage. (25) Liang et al. showed that borate glasses support the attachment and 
differentiation of human bone marrow derived mesenchymal stem cells and human 
mesenchymal stem cell derived osteoblasts. (26) 
The present study aims to fabricate three substituted BBGs to be used for bone tissue 
regeneration. We evaluated the impact of incorporating different divalent cations (i.e. 
Mg
2+
, Ca
2+
, Sr
2+
) into the BBGs on their ability to induce the BM-MSCs (known to 
differentiate into the mesodermal lineage cells, such as osteoblasts, osteoclasts and 
osteocytes (27)) to proliferate, differentiate and mineralize the ECM, while promoting 
bone formation. (11) 
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2. Experimental 
2.1. Preparation of BBGs 
The BBGs of general formula 0.05Na2O  xMgO  yCaO  (0.35-x-y)SrO  0.20B2O3  
0.40SiO2 (molar ratio, where x, y = 0.35 or 0.00, and x ≠ y) were synthesized by melt-
quenching. The suitable amounts of, silica (SiO2, Macherey-Nagel, Germany), boron 
oxide (B2O3, Alfa Aesar, Germany), sodium bicarbonate (NaHCO3, Sigma-Aldrich, 
Australia), and magnesium oxide (MgO, Sigma-Aldrich, Portugal), or calcium 
carbonate (CaCO3, Sigma-Aldrich, Portugal), or strontium carbonate (SrCO3, Sigma-
Aldrich, Portugal) were thoroughly mixed with the addition of ethanol in a porcelain 
pestle with the help of a mortar, vacuum dried overnight and transferred to a platinum 
crucible. After entirely dried, each batch was heated to 1450 ˚C in air for 1 h and 
subsequently the melt was quickly poured into cold water to form the glass frit. 
Afterwards, the as-quenched glasses were ground in an Agate mortar (RETSCH, 
Germany) and sieved to a particle size <63 μm. Before the in vitro tests BBG-Mg 
(0.05Na2O  0.35MgO  0.20B2O3  0.40SiO2), BBG-Ca (0.05Na2O  0.35CaO  
0.20B2O3  0.40SiO2) or BBG-Sr (0.05Na2O  0.35SrO  0.20B2O3  0.40SiO2) were 
weighted, dried and sterilized at 160 ºC for at least 2 h. 
2.2. Morphology and chemical composition of BBGs 
The morphology of the synthesized BBGs was observed by scanning electron 
microscopy (SEM, model S360, Leica Cambridge, UK) equipped with energy 
dispersive X-ray spectroscopy (SEM/EDS link-eXL-II) for the determination of the 
surface chemical composition. 
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2.3. Isolation and expansion of mesenchymal stem cells 
BM-MSCs were isolated from bone marrow of 4-5 week-old male Wistar rats according 
to the method established by Maniatopoulos et al. (28) and recently proposed by 
Santocildes et al. (25) BM-MSCs were expanded in basal medium consisting of 
Dulbecco’s modified Eagle’s medium (DMEM; Sigma-Aldrich, UK), supplemented 
with 100 U/ml penicillin (Sigma,-Aldrich, UK) and 1 mg/ml streptomycin (Sigma-
Aldrich, UK). Cells were cultured at 37 ºC in an atmosphere of 5% CO2. 
Prior to the in vitro studies, BM-MSCs, at passage 2, were harvested and seeded into 24 
well plates, at a density of 2×10
4
 cells per well. Cells were cultured in the presence of 
the BBGs at concentrations of 20 and 50 mg/ml, for 7, 14 and 21 days under static 
conditions. The BM-MSCs cultured in the absence of BBGs were used as negative 
control and in the presence of 45S5 bioglass
®
 as positive control. The BBGs at the 
desired concentrations and 45S5 bioglass
®
 were deposited on top of the cells, in cell 
culture inserts with porous membranes (0.4 µm ThinCerts™ Cell Culture Inserts; 
Greiner, Germany), as used in previous works. (29) The ThinCerts™ were used as an 
inert platform to support the glass particles under cell culture conditions. All BBG 
compositions and controls were cultured in basal and osteogenic differentiation media 
(basal medium supplemented with 50 µg/ml ascorbic acid, 10 mM β-glycerophosphate 
and 10
-8
 M dexamethasone). Figure 1 presents a schematic of the experimental design. 
Figure 1. Schematic of the experimental design. 
2.4. Potential cytotoxic effect of BBGs dissolution on BM-MSCs 
Cell viability and proliferation (PrestoBlue
®
 and PicoGreen
®
 assays). The 
PrestoBlue
®
 reagent (Fisher Scientific, UK) is a resazurin-based solution that is reduced 
to resorufin by viable cells which can be detected fluorimetrically. The cell viability 
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assay was executed according to the manufacturer’s instructions. In brief, the 
PrestoBlue
®
 reagent was added to a final concentration of 10% to the wells and the cells 
were incubated for 1 h at 37 
o
C. Afterwards, 200 µl samples of the culture medium were 
removed and placed in 96-well plates and the resorufin fluorescence was quantified 
spectrophotometrically using a plate reader (Tecan Infinite M200). The fluorescence 
was determined at an excitation wavelength of 560 nm and emission wavelength of 590 
nm. The metabolic activity was presented in fluorescence values and compared with the 
control (cell cultured in the absence of glass particles under basal medium conditions). 
The PicoGreen
®
 dsDNA reagent (Invitrogen, USA) is an ultrasensitive fluorescent 
nucleic acid dye for quantification of double-stranded DNA (dsDNA) in solution. This 
assay enables the measurement of cell proliferation. After each culturing period, the cell 
monolayers were washed with PBS and then incubated at 37 ºC for 3 h followed by a 
freezing step at -80 ºC for at least overnight in ultra-pure water (1 ml) to ensure cell 
lysis. The assay was performed according to the manufacturer’s protocol. And the 
fluorescence was determined at an excitation wavelength of 485 nm and emission 
wavelength of 528 nm. The DNA concentration was presented in µg/ml and compared 
with the control (cell cultured in the absence of glass particles under basal medium 
conditions). 
Cell morphology and distribution. After each culturing period the cell grown in tissue 
culture coverslips were washed with PBS and fixed with 4% formalin solution (0.5 ml) 
for 15 min at room temperature (RT). The cell layers were then washed with PBS, 
containing 0.2% Triton X, for 2 min. After the fixation and permeation steps, the cell 
monolayers were washed again with PBS and stained with 4,6-diamidino-2-phenyindole 
dilactate (1:1000 DAPI, Sigma, UK) for 2 min at RT, and phalloidin-
tetramethylrhodamine B isothiocyanate (Sigma, UK) for 1 h at RT. Finally, the cells 
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were washed and observed using an Axioplan 2 imaging fluorescent microscope with a 
digital camera QIC AM 12-bit (Zeiss, UK). 
2.5. Osteogenic capacity of BBGs on BM-MSCs 
Alkaline phosphatase quantification. The concentration of alkaline phosphatase 
(ALP) was determined for all the culture time periods, using the lysates used for DNA 
quantification. Briefly, the ALP quantity was assessed using the Alkaline Phosphatase, 
Diethanolamine Detection kit (Sigma-Aldrich, UK) in which p-nitrophenyl phosphatase 
(pNPP) solution is hydrolyzed by ALP to yellow free p-nitrophenol. In brief, a buffered 
pNPP solution was prepared and equilibrated at 37 ºC. Afterwards, 2% (v/v) of sample 
or control were added. Immediately after mixing the absorbance was read at 405 nm in a 
plate reader (Tecan Infinite M200) for ≈ 5 min. An ALP standard solution was used as 
control and buffer as blank. The units were calculated according to the following 
equation: 
                                          
       
. Where df = dilution factor; VF = 
Volume of final solution; 18.5 = millimolar extinction coefficient of pNPP at 405 nm 
and VE = Volume of samples/ALP standard solution. ALP activity was calculated by 
normalizing ALP concentration per DNA concentration for each condition and time 
point. 
Alizarin red staining. After 21 days of culture, the cells grown in tissue culture 
coverslips were fixed in 70% ice-cold methanol at -20 °C at least for 30 min. The cell 
layers were then washed with PBS and dried overnight. Afterwards, cells were stained 
with alizarin red solution [342 mg of alizarin red, (Sigma-Aldrich, UK) in 25 ml of 
distilled water and the pH was adjusted to 4.1 with 10% ammonium hydroxide (Sigma-
Aldrich, UK)] for 10 min. Afterwards, the coverslips were washed with distilled water, 
dehydrated in an acetone/xylene (Sigma-Aldrich, UK) mixture and mounted using an 
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aqueous mountant. The stained constructs were observed under an optical microscope 
(BX51, Olympus Corporation, UK) and images were captured by a digital camera 
(DP70, Olympus Corporation, UK). The BM-MSCs morphology and mineral deposition 
was also observed using SEM (model S360, Leica Cambridge, UK) equipped with 
energy dispersive X-ray spectroscopy (SEM/EDS link-eXL-II) for the determination of 
the surface chemical composition. 
Immunodetection of bone-specific proteins. Osteopontin (OP) and osteocalcin (OC) 
protein expression of BM-MSCs was assessed by immunoassay technique to evaluate 
their osteoblastic differentiation. The procedures were executed according to the 
manufacturer’s instructions. The concentrations of OP and OC were determined for all 
the culture time periods, using the lysates used for DNA quantification. The OP 
quantitative determination was performed using Mouse/Rat Osteopontin Quantikine 
ELISA Kit (R&D Systems, UK). In brief, 50 µl of assay diluent RD1W and 50 µl of 
standard (2500 to 39 pg/ml), control and samples were added and the plate incubated for 
2 h at RT. After 4 washing steps and perfectly dried, 100 µl of Mouse/Rat OP 
Conjugated were added and incubated for 2 h at RT. The sandwich complex was 
washed 4 times and allowed to react with 100 µl of substrate solution before adding 100 
µl of stop solution. Finally, the optical density was determined at 450 nm and the 
concentration of OP obtained from a standard curve plot. OC quantitative determination 
was performed by the use of Rat Gla-Osteocalcin High Sensitive EIA kit (Takara 
Clontech, Japan). In brief, 100 µl of samples and standard solution (16 to 0.25 ng/ml) 
were incubated for 1 h at 37 ºC with the capture-antibody, rat osteocalcin C-terminus-
specific antibody. After OC capture and 3 washing steps, 100 µl of the enzyme-labelled 
antibody (GlaOC4-30) specific to Gla-OC was incubated for 1 h at RT. The sandwich 
complex was washed 4 times and allowed to react with 100 µl of substrate solution for 
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10-15 min. Finally, after adding the stop solution the optical density was determined at 
450 nm and the concentration of OC obtained from a standard curve plot. OP and OC 
content was calculated by normalizing OP or OC concentration per DNA concentration 
for each condition and time point. 
2.6. Statistical analysis 
Results are expressed as mean ± standard deviation with n = 3 for each sample. Error 
bars represent standard deviations. The data was analyzed by non-parametric statistics: 
Kruskal-Wallis test (p<0.0001), followed by a Dunn’s Multiple Comparison test. *** 
p<0.001; 
**
 p<0.01; 
*
 p<0.05 in respect to the control. 
3. Results and discussion 
3.1 Morphology of BBGs and their chemical composition 
BBGs’ frits were successfully obtained by melt quenching and ground in a controlled 
manner. Figure 2a, 2b and 2c show the SEM/EDS analysis of BBGs, which exhibited an 
angular shape with low sphericity and confirmed the successful incorporation of the 
different modifier divalent cations (i.e. Mg
2+
, Ca
2+
 and Sr
2+
). The composition of BBGs 
was confirmed in a prior work by the use of X-ray fluorescence and follows the general 
formula 0.05Na2OxMgOyCaO(0.35-x-y)SrO0.20B2O30.40SiO2 (molar ratio, where x, 
y = 0.35 or 0.00, and x ≠ y). (30) Moreover, studies after immersion in SBF, showed that 
the studied BBGs are bioactive due to the formation of bone-like apatite structures onto 
their surface, and the constant release of ions to the reaction media over time. (29) 
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Figure 2. SEM/EDS micrographs of BBGs, a) BBG-Mg, b) BBG-Ca and c) BBG-Sr. 
SEM images are shown as insets, displaying the morphology of the glass particles. The 
specific modifier divalent cation is highlighted in yellow for each BBG. 
3.2 In Vitro biological evaluation 
Osteoblast differentiation can be divided into three stages: cell proliferation, ECM 
synthesis and maturation, and ECM mineralization, each with a cellular characteristic 
behavior. (31) 
3.2.1 Potential cytotoxic effect of BBGs leachables on BM-MSCs 
The effect of BBGs’ concentration on cell viability and proliferation was studied on a 
previous work. (29, 30) It showed that a concentration between 20 and 50 mg/ml did not 
significantly affect cell viability and proliferation. On the other hand, Romero et al. (32) 
studied the osteogenic response of BM-MSCs to strontium-substituted bioactive glasses 
(SrBG) and observed that 20 mg of Sr50BG promoted the osteoblastic differentiation of 
BM-MSCs. Based on these results, we decided to use BBGs concentrations of 20 and 
50 mg/ml. 
Herein, we cultured BM-MSCs in basal and osteogenic differentiation media for 7, 14 
and 21 days under static conditions, in the presence and absence of BBGs, in order to 
evaluate their biological activity. The cellular metabolism and proliferation was 
evaluated by quantifying the conversion of resazurin to resorufin by viable cells and the 
amount of double stranded DNA (live cells) in the culture wells; as well as their 
morphology. 
Fluorescence microscopy images showed the morphology of BM-MSCs in culture 
containing BBGs or 45S5 bioglass
®
 (Figure 3). The adhered BM-MSCs exhibited a 
well-spread morphology, exhibiting cell-to-cell contacts in a comparable manner on the 
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BBGs conditioned cultures as in the control experiment. While BM-MSCs cultured with 
45S5 bioglass
®
 presented a round shape for the last time point (21 days), suggesting cell 
death. At the same timepoint, especially for cultures under osteogenic differentiation 
media (e.g. BBG-Sr), there was distinguishable well-spread polygonal shape cells, 
suggesting osteoblast-like morphology. 
 
Figure 3. BM-MSCs morphology observed by fluorescence microscopy, after 7, 14 and 
21 days culture with BBGs either under basal or osteogenic culture medium. Each 
sample was incubated at two different concentrations (20 and 50 mg/ml). Cells cultured 
with basal and osteo medium were used as negative control and 45S5 bioglass
®
 
incubated with medium was used as positive control. Nuclei stained blue by DAPI; 
Actin stained green by Phalloidin. 
 
Figure 4. Metabolic activity (PrestoBlue
®
 assay) and proliferation (PicoGreen
®
 assay) 
of BM-MSCs cultured either in basal or osteogenic media in the presence of different 
concentrations (20 and 50 mg/ml) of BBG-Mg (a, b), BBG-Ca (c, d) and BBG-Sr (e, f). 
The 45S5 bioglass
®
 (g, h) was used as control. Standard culture medium was used as 
negative control. Results are expressed as mean ± standard deviation with n = 3 for each 
bar. The data was analyzed by non-parametric statistics: Kruskal-Wallis test (p<0.0001), 
followed by a Dunn’s Multiple Comparison test. *** p<0.001; ** p<0.01; * p<0.05 in 
respect to the control, i.e. BM-MSCs culture in basal media for the respective day of 
culture (i.e. 7, 14 and 21 days). 
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From the PrestoBlue
®
 data (Figure 4a, 4c, 4e and 4g) it is possible to observe that the 
metabolic activity of BM-MSCs increased over the 21 days of culture. In the first 7 days 
of culture, the BM-MSCs under conditioned cultures presented reduced viability in 
respect to the cells culture under basal condition (negative control), especially for BBG-
Ca culture conditions, which may be due to the initial burst release of ions to the media. 
In contrast, from day 14, BM-MSC cultures under osteogenic media displayed a 
reduction of metabolic activity with respect to the control (absence of glass particles and 
cell cultured under basal medium). It is noteworthy that BM-MSC cultures at day 21 
with 45S5 bioglass
®
 under osteogenic media showed very low metabolic activity when 
compared with the control experiment (osteogenic media), being consistent with the cell 
death observed by fluorescent microscopy (Figure 3). Complementary to the viability 
analysis, the cellular proliferation was also assessed by measuring the total cell DNA 
(Figure 4b, 4d, 4f, 4h). The PicoGreen
®
 data showed an increase on the number of BM-
MSCs over time. However, under osteogenic media, the cells presented lower 
proliferation rates than cultures under basal media from day 14. Noteworthy, is the 
prominent reduction of BM-MSCs for cultures with BBG-Mg (osteogenic and basal 
media) and 45S5 bioglass
®
 (osteogenic media) at day 21. To emphasize, BBG-Sr and 
45S5 bioglass
®
 under osteogenic media showed a significant reduction on the cell 
proliferation at day 14 when compared with the cells cultured under basal media, 
suggesting an alteration of biological behavior. (33) Regarding the effect of 
concentration, there was no potential toxic effects with time except in the case of BM-
MSCs cultured in the presence of BBG-Mg (osteogenic and basal media) and 45S5 
bioglass
®
 (osteogenic media) at day 21, where a large reduction in cell number was 
observed in relation to the control (basal media). 
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3.2.2 Alkaline phosphate quantification 
It is commonly accepted that ALP is a key player in the process of osteogenesis, being 
ALP known to be involved in early stages of normal and pathological calcification. (34-
36) In general, an increase of the ALP activity is correlated with osteogenesis, 
increasing during the bone formation stage. (37) Not surprisingly, the ALP 
quantification data (Figure 5) showed a significantly higher ALP activity when cells 
were cultured under osteogenic media rather than basal media. (38) However, at day 21 
the levels of ALP activity on BBG-Mg, -Sr and 45S5 bioglass
®
 cultured under 
osteogenic media are significantly higher than the cultures without glass addition (e.g. 
at day 21, under osteogenic media, the addition of 20 mg of BBG-Sr (c) induced a 
highly significant (p<0.001) enhanced ALP activity in relation to the cells cultured in 
the absence of glass particles). BBG-Mg, -Sr and 45S5 bioglass
®
 were not capable of 
inducing the ALP protein expression alone, however, they were capable to increase the 
ALP expression during the differentiation process of BM-MSCs into osteoblasts under 
osteogenic media (for 21 days of cell culture). It is relevant to point out that previous 
studies quantified the chemical species released from BBGs in solution, demonstrating a 
higher concentration of Mg
2+
 and Sr
2+
 ions (2-fold) when compared with Ca
2+
 (from 
BBG-Mg, BBGs-Sr and BBG-Ca, respectively). (29, 30) The presence of higher 
concentration of specific ions (i.e. Mg
2+
 and Sr
2+
) might facilitate cell differentiation. It 
is also relevant to highlight the fact that along with the increase of ALP activity for the 
case of BBG-Mg and -Sr glasses there was observed an increase of cell proliferation. In 
contrast, the viability and proliferation data, presented a reduction of viable and live 
cells for the BM-MSCs cultured in the presence of these BBG-Ca and 45S5 bioglass
®
. 
Remarkably, BBG-Sr promoted the increase of ALP activity for both concentrations of 
glass particles, i.e. 20 and 50 mg/ml. 
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Figure 5. ALP activity of BM-MSCs (cultured either in basal or osteogenic media) in 
the presence of different concentrations (0, 20 and 50 mg/ml) of BBG-Mg (a), BBG-Ca 
(b) and BBG-Sr (c). The 45S5 bioglass
®
 (d) was used as control. Results are expressed 
as mean ± standard deviation with n = 3 for each bar. The data was analyzed by non-
parametric statistics: Kruskal-Wallis test (p<0.0001), followed by a Dunn’s Multiple 
Comparison test. 
***
 p<0.001; 
**
 p<0.01; 
*
 p<0.05 in respect to the control, i.e. BM-
MSCs culture in basal media for the respective day of culture (i.e. 7, 14 and 21 days). 
 
3.2.3 Matrix mineralization 
Similar results were found at day 21 after alizarin red staining for mineral deposits 
(Figure 6). In agreement with ALP activity data, cells cultured under osteogenic media 
yielded more bone-like nodules (intense red spots dispersed in the cell culture), 
resulting from ECM mineralization. (35) Of importance, and corroborating with ALP 
activity data, mineral deposits were more evident with BBG-Mg, -Sr and 45S5 
bioglass
®
 (Figure 6a, 6c and 6d) and an increase of red nodules with the increase of 
concentrations can be observed in the case of the cells cultured in the presence of BBG-
Sr (Figure 6c, osteo 20 mg/ml and 50 mg/ml). Higher concentrations of BBG-Sr and 
45S5 bioglass
®
 show the presence of red nodules even in cells cultured in basal 
medium. However, ALP activity data, suggests that BBG-Sr and 45S5 bioglass
®
 (Figure 
6c and 6d basal for a concentration of 50 mg/ml) are capable to induce ECM 
mineralization by themselves. Therefore, the combination of ALP activity and 
mineralization results suggest the use of BBG-Sr to promote osteogenesis. (39) 
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Figure 6. Alizarin red staining of BM-MSCs cultured during 21 days, either in basal or 
osteogenic media in the presence of different concentrations (20 and 50 mg/ml) of 
BBG-Mg (a), BBG-Ca (b) and BBG-Sr (c). The 45S5 bioglass
®
 (d) was used as control. 
 
Figure 7. SEM micrographs of BM-MSCs in the presence of different concentrations 
(20 and 50 mg/ml) of BBG-Mg (a), BBG-Ca (b) and BBG-Sr (c) after 21 days of cell 
culture either in basal or osteogenic media. Higher SEM magnifications are shown as 
insets, highlighting the formed apatite-like structures. The 45S5 bioglass
®
 was used as a 
control. 
In Figure 7 we presented SEM micrographs of BM-MSCs cultured for 21 days in the 
presence of BBGs and 45S5 bioglass
®
. In the images it is possible to observe the 
deposition of minerals over the dense layer of cells, when they were cultured in the 
presence of BBG-Mg, -Sr and 45S5 bioglass
®
 (Figure 7a, 7c and 7d). The presence of 
these glass compositions in the culture medium promoted a mineralization typical to 
occur while BM-MSCs differentiate into osteoblasts. (38) This mineralization is in 
agreement with the alizarin red data where the mineral deposits were more evident in 
the cells cultured in the presence of BBG-Mg, -Sr and 45S5 bioglass
®
 (Figure 6a, 6c 
and 6d). In these culture conditions, it is observed in the SEM/EDS images calcium 
phosphate deposits over the dense cellular layer. Once more, higher concentrations of 
BBG-Sr and 45S5 bioglass
®
 under basal culture conditions promoted the deposition of a 
higher amounts of calcium phosphate structures, suggesting that BBG-Sr and 45S5 
bioglass
®
 (Figure 7c and 7d basal for a concentration of 50 mg/ml) are capable of 
inducing ECM mineralization by themselves, which could be beneficial for bone 
regeneration. (39) 
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3.2.4 Protein expression (OP and OC) 
Complementary to the reported biological data, the differentiation level of BM-MSC, 
cultured in the presence (20 and 50 mg/ml) and absence of BBG-Mg, -Ca, -Sr and 45S5 
bioglass
®
 (either in basal or osteogenic media) was assessed by the quantification of the 
expression level of two major bone-specific proteins, i.e. OP and OC. The relative 
expression of these proteins was normalized in relation to the number of cells, i.e. 
amount of dsDNA. It is well known that osteoblasts are differentiated cells that 
mineralize the bone matrix. OP is a phosphoprotein synthesized by bone forming cells, 
which present calcium-binding domains and is responsible for cell attachment, 
proliferation, and ECM mineralization. (40) In the case of OC, it is a bone-specific 
glycoprotein capable of binding to calcium, which promotes ECM calcification. (40) 
Not surprisingly, the OP and OC quantification data (Figure 8 and Figure 9) showed a 
significantly higher protein expression when BM-MCSs were cultured under osteogenic 
media rather than basal media. (41) In the case of OP, as expected, a delay in the protein 
synthesis is observed (Figure 8). At day 7 there was no significant difference of OP 
expression in relation to the control (absence of glass particles and cell culture in basal 
medium). However, at day 14 there is a high expression peak by BM-MSCs cultured in 
osteogenic medium (in the presence of BBG-Mg, -Sr and 45S5 bioglass
®
), which 
determines the decay of the matrix deposition phase and the beginning of the 
mineralization phase. Moreover, BBG-Sr and 45S5 bioglass
®
 continue to induce a 
significant overexpression of OP over time (e.g. at day 21), supporting the 
mineralization demonstrated by ALP and alizarin red analysis (Figure 5 and 6, 
respectively). In the OC case there was a high protein expression up to day 14, 
indicating bone ECM maturation (Figure 9). (42) At day 7 there is a significant 
difference in OP expression in relation to the control (cell culture in basal medium and 
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in the absence of glass particles). After day 7 there was a reduction of OC expression, 
consistent with matrix mineralization. Noteworthy is the observation that BBG-Sr under 
basal medium induced the BM-MSCs to exhibit a peak of OC expression at day 14. 
This data suggested that the BBG-Sr glass particles (at a concentration of 50 mg/ml) 
induced the OC protein expression, which is in agreement with the ALP and alizarin red 
data. Also, BBG-Sr and 45S5 bioglass
®
 prolonged the OC overexpression over the 21 
days of culture. In addition, the 45S5 bioglass
®
 promoted a high deposition of OC at 
day 21 (Figure 4h) compared with high BM-MSCs density in the case of BBG-Sr 
(Figure 4f). However, it is important consider that in the case of the cultures in the 
presence of 45S5 bioglass
®
 a very low BM-MSCs cell density was observed, which 
might be related with the cytotoxicity of 45S5 bioglass
®
. (43) Therefore, and overall, 
our data suggests that the BBG-Sr glass particles are able to induce the BM-MSCs to 
express higher levels of OP and OC, while maintaining the BM-MSCs cell density. 
 
Figure 8. OP protein content of BM-MSCs cultured either with basal or osteogenic 
media in the presence of different concentrations (20 and 50 mg/ml) of BBG-Mg (a), 
BBG-Ca (b) and BBG-Sr (c). The 45S5 bioglass
®
 (d) was used as control. Results are 
expressed as mean ± standard deviation with n = 3 for each bar. The data was analyzed 
by non-parametric statistics: Kruskal-Wallis test (p<0.0001), followed by a Dunn’s 
Multiple Comparison test. 
***
 p<0.001; 
**
 p<0.01; 
*
 p<0.05 in respect to the control, i.e. 
BM-MSCs culture in basal media for the respective day of culture (i.e. 7, 14 and 21 
days). 
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Figure 9. OC protein content of BM-MSCs cultured either with basal or osteogenic 
media in the presence of different concentrations (20 and 50 mg/ml) of BBG-Mg (a), 
BBG-Ca (b) and BBG-Sr (c). The 45S5 bioglass
®
 (d) was used as control. Results are 
expressed as mean ± standard deviation with n = 3 for each bar. The data was analyzed 
by non-parametric statistics: Kruskal-Wallis test (p<0.0001), followed by a Dunn’s 
Multiple Comparison test. 
***
 p<0.001; 
**
 p<0.01; 
*
 p<0.05 in respect to the control, i.e. 
BM-MSCs culture in basal media for the respective day of culture (i.e. 7, 14 and 21 
days). 
 
Hence, combining the obtained biological data, i.e. viability, proliferation, 
mineralization and protein expression analysis (ALP, OC and OP), we were able to 
identify the BBG-Mg, -Sr (at concentrations of 20 to 50 mg/ml) as relevant promoters 
of the osteogenic differentiation of BM-MSCs. Several authors reported that Mg
2+
 ions 
significantly enhanced osteoblast adhesion by the altering cell-matrix interactions, 
which modulate the function of integrins related with cell differentiation. (19, 44) Our 
results suggest that BBG-Mg also promoted BM-MSCs differentiation, which might be 
related with the presence of Mg
2+
 in the culture medium. Remarkably, BBG-Sr (at a 
concentration of 50 mg/ml and 21 days of culture) presented the capacity to induce 
osteogenic response in BM-MSCs in the absence of osteogenic medium. Other authors 
reported Sr containing glasses to stimulate osteoblast metabolic activity, inhibiting 
osteoclast differentiation, as well as promoting the increment of ALP activity. (24) For 
instance, Hurtel-Lemaire et al. (45) have shown that Sr induces osteoclast apoptosis at 
concentrations higher than 9 mM. This is in accordance with our previous studies (29) 
that demonstrated a concentration of Sr in the culture media of about 20 mM after 3 
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days of culture. The ALP activity results showed the shift of BM-MSCs to a more 
differentiated state, while the alizarin red analysis demonstrated that the cells in the 
presence of BBG-Mg and BBG-Sr glass particles present intense and dispersed red 
spots in the cell culture, corresponding to the mineralization promoted by the BM-
MSCs. Finally, Santocildes et al. (25) demonstrated that the dissolution of Sr-containing 
glasses stimulated the upregulation of genes associated with the process of osteogenic 
differentiation, such as Bglap (OC) and Spp1 (OP). In agreement with this data, we also 
observed that BBGs-Mg an BBG-Sr might also influence the ECM maturation and 
mineralization, through the promotion of the OP and OC protein overexpression, which 
suggests that these glass compositions may be effective in inducing and sustaining the 
osteoblastic phenotype. (46) 
4. Conclusion 
BBGs with different substituted divalent cations (Ca
2+
, Sr
2+
 or Mg
2+
) were successfully 
synthesized by melt quenching. In vitro studies demonstrated that the studied BBGs 
exhibit the capability to improve the osteogenic differentiation of BM-MSCs with no 
deleterious effects over cell viability and proliferation. Specially, BBG-Mg and BBG-Sr 
(at 20 and 50 mg/ml) provided favorable conditions for BM-MSCs to differentiate to 
osteoblast-like cells and induce the formation of a high amount of mineralized nodules. 
The phenotypic expression of two major bone-specific proteins, namely, OP and OC 
confirmed the osteogenic potential of the BBGs. 
The findings that the BBGs are able to promote in vitro cell differentiation into an 
osteogenic lineage, support their potential application in regenerative medicine. Based 
on these promising results we propose the incorporation of these BBGs into 
biomaterials for bone regeneration. The proposed BBGs are also relevant candidates for 
further in vivo evaluation. 
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Figure 1. Schematic of the experimental design. 
Figure 2. SEM/EDS micrographs of BBGs, a) BBG-Mg, b) BBG-Ca and c) BBG-Sr. 
SEM images are shown as insets, displaying the morphology of the glass particles. The 
specific modifier divalent cation is highlighted in yellow for each BBG. 
Figure 3. BM-MSCs morphology observed by fluorescence microscopy, after 7, 14 and 
21 days culture with BBGs either under basal or osteogenic culture medium. Each 
sample was incubated at two different concentrations (20 and 50 mg/ml). Cells cultured 
with basal and osteo medium were used as negative control and 45S5 bioglass
®
 
incubated with medium was used as positive control. Nuclei stained blue by DAPI; 
Actin stained green by Phalloidin. 
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Figure 4. Metabolic activity (PrestoBlue
®
 assay) and proliferation (PicoGreen
®
 assay) 
of BM-MSCs cultured either in basal or osteogenic media in the presence of different 
concentrations (20 and 50 mg/ml) of BBG-Mg (a, b), BBG-Ca (c, d) and BBG-Sr (e, f). 
The 45S5 bioglass
®
 (g, h) was used as control. Standard culture medium was used as 
negative control. Results are expressed as mean ± standard deviation with n = 3 for each 
bar. The data was analyzed by non-parametric statistics: Kruskal-Wallis test (p<0.0001), 
followed by a Dunn’s Multiple Comparison test. *** p<0.001; ** p<0.01; * p<0.05 in 
respect to the control, i.e. BM-MSCs culture in basal media for the respective day of 
culture (i.e. 7, 14 and 21 days). 
Figure 5. ALP activity of BM-MSCs (cultured either in basal or osteogenic media) in 
the presence of different concentrations (0, 20 and 50 mg/ml) of BBG-Mg (a), BBG-Ca 
(b) and BBG-Sr (c). The 45S5 bioglass
®
 (d) was used as control. Results are expressed 
as mean ± standard deviation with n = 3 for each bar. The data was analyzed by non-
parametric statistics: Kruskal-Wallis test (p<0.0001), followed by a Dunn’s Multiple 
Comparison test. 
***
 p<0.001; 
**
 p<0.01; 
*
 p<0.05 in respect to the control, i.e. BM-
MSCs culture in basal media for the respective day of culture (i.e. 7, 14 and 21 days). 
Figure 6. Alizarin red staining of BM-MSCs cultured during 21 days, either in basal or 
osteogenic media in the presence of different concentrations (20 and 50 mg/ml) of 
BBG-Mg (a), BBG-Ca (b) and BBG-Sr (c). The 45S5 bioglass
®
 (d) was used as control. 
Figure 7. SEM micrographs of BM-MSCs in the presence of different concentrations 
(20 and 50 mg/ml) of BBG-Mg (a), BBG-Ca (b) and BBG-Sr (c) after 21 days of cell 
culture either in basal or osteogenic media. Higher SEM magnifications are shown as 
insets, highlighting the formed apatite-like structures. The 45S5 bioglass
®
 was used as a 
control. 
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Figure 8. OP protein content of BM-MSCs cultured either with basal or osteogenic 
media in the presence of different concentrations (20 and 50 mg/ml) of BBG-Mg (a), 
BBG-Ca (b) and BBG-Sr (c). The 45S5 bioglass
®
 (d) was used as control. Results are 
expressed as mean ± standard deviation with n = 3 for each bar. The data was analyzed 
by non-parametric statistics: Kruskal-Wallis test (p<0.0001), followed by a Dunn’s 
Multiple Comparison test. 
***
 p<0.001; 
**
 p<0.01; 
*
 p<0.05 in respect to the control, i.e. 
BM-MSCs culture in basal media for the respective day of culture (i.e. 7, 14 and 21 
days). 
Figure 9. OC protein content of BM-MSCs cultured either with basal or osteogenic 
media in the presence of different concentrations (20 and 50 mg/ml) of BBG-Mg (a), 
BBG-Ca (b) and BBG-Sr (c). The 45S5 bioglass
®
 (d) was used as control. Results are 
expressed as mean ± standard deviation with n = 3 for each bar. The data was analyzed 
by non-parametric statistics: Kruskal-Wallis test (p<0.0001), followed by a Dunn’s 
Multiple Comparison test. 
***
 p<0.001; 
**
 p<0.01; 
*
 p<0.05 in respect to the control, i.e. 
BM-MSCs culture in basal media for the respective day of culture (i.e. 7, 14 and 21 
days). 
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